Halozyme Inc - Company & Market Research Reports

Halozyme was founded in 1998, the headquarters are located in San Diego, California. It is a biotechnology company that innovates cancer therapies that target the tumor microenvironment. PEGPH20, their main proprietary programme applies a unique approach to targeting solid tumors it may help make existing treatments more effective by allowing therapies to reach the tumor. Halozyme has teamed up with many partnering companies such as: Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly for the NHANZE™ drug delivery technology platform.

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018

  • Report
  • 385 Pages
From
Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence - Product Thumbnail Image

Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence

  • Report
  • 170 Pages
From
Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence - Product Thumbnail Image

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence

  • Report
  • 171 Pages
From
Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030 - Product Thumbnail Image

Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030

  • Report
  • 350 Pages
From
Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

  • Report
  • 244 Pages
From
Global Breast Cancer Therapeutics Market Analysis 2016 - Forecast to 2022 - Product Thumbnail Image

Global Breast Cancer Therapeutics Market Analysis 2016 - Forecast to 2022

  • Report
  • 157 Pages
From
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update - Product Thumbnail Image

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update

  • Report
  • 462 Pages
From
United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices - Product Thumbnail Image

United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices

  • Report
  • 980 Pages
From
Prefilled Syringes Market (4th Edition), 2017-2026 - Product Thumbnail Image

Prefilled Syringes Market (4th Edition), 2017-2026

  • Report
  • 525 Pages
From
Large Volume Wearable Injectors Market (3rd Edition), 2017-2027 - Product Thumbnail Image

Large Volume Wearable Injectors Market (3rd Edition), 2017-2027

  • Report
  • 365 Pages
From
Immune Checkpoint Inhibitors: Clinical Trial Tracker - Product Thumbnail Image

Immune Checkpoint Inhibitors: Clinical Trial Tracker

  • Clinical Trials
From
Contact Dermatitis - Pipeline Insight, 2018 - Product Thumbnail Image

Contact Dermatitis - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Bolus Injectors Market, 2014 - 2024 - Product Thumbnail Image

Bolus Injectors Market, 2014 - 2024

  • Report
  • 179 Pages
From
Pancreatic Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Pancreatic Cancer - Pipeline Review, H1 2018

  • Drug Pipelines
  • 2509 Pages
From
Large Volume Injection Devices for Self-Administration - Product Thumbnail Image

Large Volume Injection Devices for Self-Administration

  • Report
From
Antibody Drug Conjugates Market (4th Edition) 2017-2030 - Product Thumbnail Image

Antibody Drug Conjugates Market (4th Edition) 2017-2030

  • Report
  • 556 Pages
From
Pancreatic Cancer: Opportunity Analysis and Forecast to 2026 - Product Thumbnail Image

Pancreatic Cancer: Opportunity Analysis and Forecast to 2026

  • Report
  • 225 Pages
From
Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016

  • Drug Pipelines
  • 250 Pages
From
Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2018 - Product Thumbnail Image

Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 - Product Thumbnail Image

Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

  • Report
  • 205 Pages
From
Loading Indicator
adroll